

A Review on Microparticles Drug Delivery System

Ankita Kishor Soni¹, Sulbha. G. Patil²

¹Department of Pharmaceutics, PSG Vidhya Prasarak Mandal's College of Pharmacy, Shahada 425409, India

Submitted:25-07-2023

Accepted: 05-08-2023

ABSTRACT - Microparticles, microspheres, and microcapsules are frequently used in multiparticulate drug delivery strategies due to their advantages in both medicine and technology. Microparticles are utilized as multiunit drug conveyance frameworks with welldefined physiological and pharmacokinetic advantages to build viability, resilience, and patient consistence. They range in size from one millimeter to one thousand millimeters. A variety of polymers have been used to make microparticles for drug delivery research to make them more effective and less harmful. Today, polymers, ceramic, and glass are used to make microparticles.

Liposomes are less stable than microparticles in the biological environment. Microparticles can contain a targeting moiety that is surface-linked. This method is utilized to deliver drugs to specific locations. Microparticles are also used for controlled, long-term release. Macromolecules are encased within microparticles for the purpose of treating a variety of diseases, including inflammation, ophthalmic disorders, cancer, and cardiac conditions. The advantages and disadvantages of microparticles, as well as their types, preparation methods, evaluations, and applications, are discussed in this review.

Keywords- Microparticles, Microspheres, Microcapsules, Polymer Microsphere, Matrix,

carrier for microparticulate administration. It has been demonstrated that microparticles are an excellent method for preparing sustained and controlled release dosage forms. They are also a useful method for administering pharmacologically active APIs, which are difficult to administer due to their limited solubility in water. It can be challenging to achieve high C_{max}, T_{max}, and AUC in these drugs. As a result, these agents-containing immediate release products are required. Microsphere-based definitions can be formed to give a consistent medication focus in the blood or to target medications to explicit cells or organs




Figure 1-MICROPARTICLES

I. INTRODUCTION

One method for delivering drugs over extended periods of time in a controlled and sustained manner is the microparticulate drug delivery system. They are small solid particles or liquid droplets surrounded by natural and synthetic polymer films of varying thickness and permeability that control the release rate and have a diameter of up to 0.1 μ m to 200 μ m.

At first utilization of egg whites microspheres in drug conveyance framework was proposed by Kramer in 1974. Microspheres as sustained release vehicles were (A, 2023)proposed by Java Krishna & Catha in 1997. Hemoglobin has also been reported as a natural, biodegradable drug

ADVANTAGES OF MICROPARTICLES

As of late, controlled discharge has turned into an extremely valuable device in drug region, offering an extensive variety of genuine and seen benefits to the ongoing illnesses like rheumatoid joint inflammation, osteoarthritis, furthermore, outer muscle problems including degenerative joint conditions actually request long haul treatment. The following advantages in dosage forms were noted with the introduction of microparticles:

- (1) Effective delivery of insoluble or sparingly soluble agents in water.
- (2) They offer products with immediate release properties and the potential to provide 80% or more

of N.V. Satheesh Madhav et al./International J. PharmTech Res.2011,3(3) 1243

dynamic specialist in around 10 minutes or less. Ex.

Nimesulide

(3) The strategy gives the best approach to moving along taste of a functioning specialist.

(4) They improved the drugs' relative bioavailability.

(5) The detailing of microparticles likewise gives the technique for focusing on the medication conveyance to explicit locales.

(6) The microparticles have a great deal of potential for reducing the frequency of drug dosages and their toxicity.

(7) Microparticles as microcapsules can likewise be utilized as transporter for drugs and immunizations as

analytic specialists and in surgeries.

(8) Amorphous drugs with desirable physical properties can also be made using them.

(9) They likewise caused the decrease of the neighborhood side impacts ex. GI irritation and other effects of drugs taken orally.

(10) They offer a sustained release formulation with a lower drug dose for better patient compliance and maintaining plasma concentration.

(11) The PH-triggered microparticles are utilized in gene therapy, transfection, and vaccination.

(12) Parental microparticles have the advantage of administering water-soluble drugs in high concentrations without causing severe osmotic effects at the site of administration.

(13) They additionally enjoy a benefit of being put away in dry molecule or suspension structure with almost no

loss of action over a lengthy stockpiling period.

(14) They are useful for administering effervescent medication to people who are unable to chew. Ex. The elderly and debilitated patients who have difficulty swallowing solids.

(15) On the other hand, smaller microparticles must be prepared before being applied to other locations like the eye, lungs, and joints.

DISADVANTAGES OF MICROPARTICLES

Despite their impressive appearance, the minute particles do have a few drawbacks:

1) "Compared to standard formulations, controlled release formulations have higher material and processing costs."

2) What happens to the polymer matrix and how it affects the environment 3) Polymer additives

include fillers, stabilizers, antioxidants, plasticizers, and others.

4) The process is not repeatable.

5) The stability of the drug can be affected by changes in temperature, pH, and the addition of solvents.

6) Particles agglomerate because of their small size and large surface area, making it difficult to physically handle microparticles in both liquid and dry forms.

7) Before micro particles can be used in clinical settings, these issues must be resolved.

II. TYPES OF MICROPARTICLES

Microparticle are mainly divided into two types specifically-




Figure 2- Types of Microparticles

MICROSPHERE

"Microspheres are free streaming powder which is comprised of circular particles having measurement < 200 distance across. Using a needle with a number of 18 or 20, it can be injected. They are comprised of biodegradable proteins or manufactured polymers tracked down in nature. In addition to enhancing a medication's therapeutic efficacy, a well-designed controlled drug delivery system can address some of the drawbacks of conventional therapy.

Types of Microsphere

- Bioadhesive Microsphere
- Floating Microsphere
- Radioactive Microsphere
- Magnetic Microsphere
- Polymer Microsphere

MICROCAPSULE

"This strategy for epitome a substance inside a little container is called as microencapsulation. Microcapsules are little circles encircled by a homogeneous wall. The

microcapsule's shell and coating are both referred to as the shell/coating, while the core/internal phase is referred to as the core/internal phase. The size of a microcapsule varies from 1 to 7 mm. Solids, fluids, and gases can all be encapsulated, which can change the size and design of cases."

REASONS OF MICROCAPSULATIONS

- 1) "This procedure has been generally used to hide the taste and scent of different drugs to increment patient consistence.
- 2) Drugs can be made to flow freely into powder using this technology.
- 3) Medication that are susceptible to oxygen, moisture, or light can be stabilized through the use of microencapsulation.
- 4) Microencapsulation can be utilized to forestall drug incongruence.
- 5) Methyl salicylate and peppermint oil are two examples of volatile medications that can be prevented from vaporizing through microencapsulation.
- 6) To reduce toxicity and GI irritation, many medications, such as ferrous sulfate and KCl, have been microencapsulated.
- 7) Changing the absorption site can also be accomplished through microencapsulation.
- 8) To reduce the likelihood of factorial person sensitization, toxic substances, such as pesticides, can be microencapsulated.
- 9) Bakan and Anderson claim that microencapsulated vitamin A palmitate has improved stability.

III. PREPARATION OF MICROPARTICLE

A. Single Emulsion Process:

"Oil-in-water (o/w) emulsification is utilized in this methodology. A volatile solvent containing dissolved polymer, the medication to be encapsulated, and a dissolved surfactant make up the organic phase of the O/W emulsion system.

The fluid stage contains a surfactant that keeps the natural drops from blending whenever they have formed. The polymer-solvent medication solution is emulsified (at the appropriate temperature and agitation) to produce an o/w emulsion. Using a propeller or magnetic bar, the

organic and aqueous phases are mixed together to create the emulsion.

Surfactants are used to stabilize the dispersed phase droplets that are produced during emulsification and prevent coalescence.

As amphiphilic substances, surfactants will align themselves at the surface of a droplet, lowering the free energy at the interface between the two phases and increasing stability.

The surfactant also provides resistance to microsphere flocculation and coalescence. PVA is an ordinarily used surfactant in the development of microparticles."

B. Double Emulsion Process:

"The double emulsion process is frequently utilized for medications that are insoluble in organic solvents." In the event that the medication's structure is little enough, a strong in-oil-in-water emulsion(s/o/w) technique could be utilized to exemplify it. The drug crystal should be at least an order of magnitude smaller than the diameter of the target microparticle in order to avoid the massive bursts that occur when larger crystals dissolve.

Smaller crystals will be evenly distributed throughout the organic droplet of the emulsion. Encapsulating hydrophilic medicines like cisplatin and doxorubicin has been done this way.

The problem with encapsulating hydrophilic drugs is that the remaining drug may migrate to the surface of the droplet before solidifying if it is lost to the external aqueous phase during the process.

To diminish the probability of these issues, the natural drop ought to be merged into microparticles when practical later creation.

This is achieved by joining a thick natural polymer and medication arrangement with a huge optional volume of water, which brings the natural dissolvable into the fluid stage rapidly, leaving the typified drug in the microparticle. The organic solvent can be removed from the droplet more quickly because the viscous dispersion phase makes it smaller. Additionally, it makes it harder for the solid drug particle or crystal to migrate to its surface, which results in a more even distribution of the drug within the particle.




Figure 3 – Double Emulsion Method

C. Phase Separation:

A third component is added to the polymer solution to reduce the polymer solution and the encapsulating polymer's solubility." Two liquid phases are produced by the method: a coacervate phase containing polymers and a supernatant phase devoid of polymers.

The coacervate coats the prescription that is scattered/broke down in the polymer arrangement. coacervation process having the accompanying three stages:

- 1) The polymer solution's phase separation, and
- 2) Coacervate adsorption around the drug particle.
- 3) Hardening of the microspheres.

D. Spray Drying :

"Spray drying is a common process in the pharmaceutical industry, and a number of researchers have looked into using it to produce biodegradable microparticles. It is quick, simple, and easy to scale up. It only needs mild conditions, and it relies less on factors that affect the solubility of drugs and polymers.

In this method, the medication is typically dissolved or suspended in a polymer solution. The arrangement/suspension is then conveyed into the splash drying gadget by means of the spout, where the polymer/drug arrangement is immediately joined with air and passed through a little distance across opening. At nozzle 25, the polymer/drug solution is nebulized, and before being collected,

the resulting droplet is immediately dried by evaporation.




Figure 4 – Spray Dryer

E. Fluidized Bed Coating:

"Top, bottom, and tangential are three popular methods of fluidized bed coating." The bulk density of the formed granules is typically low due to the porous surface and interstitial void area that granules frequently possess. The digressive splash covering process utilizes a mix of radiating, high-thickness blending and liquid bed drying effectiveness to create an item with a high mass thickness however, some interstitial void space. It produces particles that are more spherical and less friable. In the bottom spray method, the solid core

particles are fluidized by air pressure and sprayed with a solution from the bottom of the fluidization chamber, which is similar to the air stream. 22] The spraying nozzle, which is suspended in the air, sprays the coating materials into the fluidized particles. The film is distributed more evenly because the droplets of the coating solution only travel a short distance before coming into contact with the solid particles.

From that point forward, the covered particles are raised up high stream, which dries the covering. After that, the particles that were thrown into the air stream settle, and a new cycle begins."




Figure 5 – Fluidized Bed Coating

F. Solvent/Emulsion Extraction Process:

"In this method for the production of microparticles, the organic phase is removed through the extraction of the organic solvent. This procedure makes use of organic solvents that dissolve in water, like isopropanol. The organic phase is removed when water is used as a solvent in extraction. The microspheres' hardening time is shortened as a result of this procedure. The preparation of microparticles necessitates the polymer's dissolution in a solvent. After that, the solution is emulsified in vegetable oil, and an amphiphilic agent is added to the emulsion to help with solvent extraction, which results in the formation of tiny particles.



Figure 6 – Solvant Exarction

IV. EVALUATIONS OF MICROPARTICLES

The following are the various evaluation methods for microparticle preparation:

1. determining the size and shape of particles: It very well may be done by microscopy, sifter investigation, laser lightdissipating, coulter counter technique, photon relationship spectroscopy.

- Crystallinity can be assessed by differential filtering calorimetry investigation.

Both freezes etch electron and freeze fracture microscopy can be used to examine surface morphology and shape. The size range of the microparticles can also be measured using a laser diffractometer and light microscope.

- A set of standard sieves with meshes ranging from 10 to 100 can be used to conduct a size analysis on all of the prepared microparticle batches. The microparticles are gone through the arrangement of strainers also, the sum held on each sifter is gauged. The total weight size is divided by 100 to get the arithmetic average diameter.

2. Bulk and Tap Density: The microparticles' bulk and tap densities are also evaluated. Mercury or Helium intrusion potentiometry can also be used to measure porosity in a specific area. Stream properties of microparticles can be assessed by deciding the point of rest byfixed pipe and freestanding cone strategy and the compressibility file bytapped thickness strategy.

3. The Thermal Properties: Differential scanning calorimetry measurement and thermogravimetric analysis are used to determine the thermal properties.

The amount of heat required to raise the sample and reference temperature in differential scanning calorimetry, or DSC, is measured as a function of temperature. Throughout the duration of the experiment, the temperature of the sample and the reference is nearly identical. For the most part, a DSC analysis's temperature program is set up so that the temperature of the sample holder rises linearly over time. Over the temperature range that will be scanned, the reference sample should have a heat capacity that is clearly defined.

4. Electrostatic collaboration is recognized by rheological & FTIR tests (Fourier Transform Infra red spectroscopy) utilizing potassium bromide pellets.

5. HPLC can be used to evaluate **peptide entrapment and entrapment effectiveness.**

6. The drug release studies were evaluated using the USP method II or the dissolution test method with phosphate buffer PH 6.8 and a temperature of 37 ± 0.5 for the release medium, followed by spectrophotometric testing.

V. APPLICATIONS OF MICROPARTICLES

1. Cosmetics, diagnostic aids, biological filtration devices, veterinary and zoo technical products, foods and food additives, flavors, fragrances, detergents, paints, agricultural chemicals, adhesives, industrial chemicals, household products, packaging, textiles, photographic and graphic arts materials, and pharmaceutical and biotechnology products are all examples of applications for microcapsules.

2. These microcapsules are crucial for providing a sustained and controlled release, enhancing drug stability, lessening the vaporization of volatile oils, safeguarding drugs that are sensitive to moisture, light, and oxidation, masking an unpleasant taste and smell, transforming liquids into powders, and separating substances that are incompatible within a single system.

3. Some examples of encapsulated antibiotics include amoxicillin, ampicillin, bacampicillin, cephalexin, cephadrine, chloramphenicol, clarithromycin, erythromycin, potassium pheneticillin, ofloxacin, and ciprofloxacin.

4. Another category of medications that benefit from microencapsulation is those that treat inflammation.

Examples of encapsulated drugs in this category include diclofenac sodium, flufenamic acid, glaphenine, hydrocortisone, ibuprofen, indomethacin, naproxen, oxyphenbutasone, and prednisone.

5. Encapsulated sulfa drugs include sulfadiazine, sulfamethizole, sulfamethoxazole, sulfamerazine, and sulfisoxazole.

6. Furosemide, chlorothiazide, and sulfonamide were epitomized to plan supported discharge details that would offer the upside of staying away from brief times of top diuresis saw with the ordinary details

7. Microencapsulated antihypertensives include isosorbide-5-mononitrate (IS-5-MN), dihydralazinesulfate, pirtanide and propranolol HCl, captopril, nicardipin, and dipyridamole. IS-5-MN microcapsules were developed with the goal of maintaining the drug's effect and overcoming the tolerance that was developed in conventional preparations

8. Nutrients A, B1, B2, B6, B12, C, D, were embodied to give arrangement of smooth-and thick-walled microcapsules to a great extent forestalled the collection of microcapsules and showed low disintegration rate.

9. Coating and Recovering Oil Droplets as Fine Powders Citrus essential oil, cod liver oil, benzaldehyde, and carbon tetrachloride were transformed into free-flowing powders. The strong capsule wall, which prevents vaporization and oxidation, appears to be influenced by the bulk droplet size of the encapsulated material, according to the authors.

10. Air filled miniature particles are utilized in echocardiography and other ultrasonic imaging strategies. They are likewise utilized as opacifier or reflectivity enhancers in beauty care products.

11. Polypeptides, insulin, somatostatin, and metolopromide are just a few examples of drugs that can be delivered through the nose with the help of solid microspheres.

12. PH set off miniature particles have been utilized to convey drugs by different means ex- by IV infuse, intra dermal inj, rectally, orally, intravaginally, inhalationally, mursal conveyance and so forth.

13. Additionally, they are administered. a tumor or pathogen's antigenic epitope.

14. The microparticles are useful for gene therapy and cell transfer.

15. For dye, antibodies, and stable strong kits, condensed phase microparticles are used.

REFERENCES

- [1]. Lwise Donald, Handbook of Pharmaceutical Controlled Release Technology, New York, 2000; 271.
- [2]. Us. Patent Wo/2000/O32166 Published In., 1999; April 15.
- [3]. Jain Nk. Controlled and Novel Drug Delivery, 4th Edition, New Delhi: cbs Publishers and Distributers., 2002; 236-237.
- [4]. Lin Y, Paschalis A. Physicochemical Aspects of Drug Delivery And Release From Polymer- Based Colloids. Curr. Opin. Colloid Interfac. Sci., 2000; 5: 132-143.
- [5]. James Swar Brick, James Boylan E, Mercel Dekkar. Microencapsulation technology and applications. Encyclopedia of pharmaceutical Technology. 1988;10:245-286.
- [6]. Kinam Park, Yoon Yeo. Microencapsulation technology encyclopedia of pharmaceutical technology GEPT. 2002;6(2):67-85.
- [7]. Jain N K, Controlled and Novel drug delivery, (2004), 236- 237, 21.
- [8]. Ganesan P, Deepa John AJ, Sabapathy L, Duraikannu A. Review on Microsphere. American J of Drug Discovery and Development. 2014;4(3):153-179. doi:10.3923/ajdd.2014.153.179.
- [9]. Kaushik A, Tiwari A, Gaur A. Role of excipients and polymeric advancements in preparation of floating drug delivery systems. Int J Pharma Investig. 2015;5(1):1. doi:10.4103/2230-973X.147219
- [10]. Guojun Liu, Husheng Yang, Jiayun Zhou, Preparation of magnetic microsphere from water-in- oil emulsion stabilized by block copolymer dispersant, Biomacromolecules , 6, 2005, 1280-1288.
- [11]. I. Genta , P. Perugini , F. Pavanetto , K. Maculotti, T. Modena , B. Casado , A. Lupib, P. Iadarolab, B. Contia Enzyme loaded biodegradable microspheres in vitro ex vivo evaluation. Journal of Controlled Release 77, 2001, 287-295.
- [12]. S.P.Vyas and R.K.Khar, Targeted and Controlled drug delivery, 07 Edition, 418.
- [13]. Ramteke K.H, Jadhav V.B, Dhole S.N. Microspheres: as carriers used for novel drug delivery system IOSR Journal of Pharmacy (IOSRPHR) ISSN: 2250-3013, Vol. 2, Issue 4 (July 2012), PP 44-48.
- [14]. Leon L, Herbert AL and Joseph LK (1990). The Theory and Practice of Industrial Pharmacy, 3rd edition (Varghese Publishing House) 412, 428.
- [15]. James S, Encyclopedia of Pharmaceutical Techonology, 3rd edition, Vol-1325-1333.
- [16]. Jadupati, M., Tanmay, D., Souvik, G. 2012: Microencapsulation: An indispensable technology for drug delivery system. Int. Res. J. Pharm. 3(4); 8-13.
- [17]. Umer, H., Nigam, H., Tamboli, A. 2011: Microencapsulation: Process, technique and applications. Int. J. Res. Pharm. Biomed. Sci. 2(2); 474-481.
- [18]. Jain RA, The manufacturing techniques of various drug loaded biodegradable (lactide-/co-/glycolide) (PLGA) devices. Biomaterials, 21(23), 2000,2475-2490.
- [19]. Jail R Nixon JR, Biodegradable poly(lactic acid) and poly (lactide-coglycolide) microcapsules; problems associated with preparative techniques and release property, Journal of Microencapsulation, 7(3), 1990, 297-325.
- [20]. Jeyanthi R, Effect of solvent removal technique on the matrix characteristics of polylactide / glycolide microsphere for peptide delivery, Journal of controlled Release, 38(2,3), 1996, 235.
- [21]. Arshady R, Preparation of biodegradable microsphere and microcapsules: 2. Polyactides and related polyesters, Journal Of Controlled Release, 17(1), 1991, 1-22.
- [22]. Veronica Lassalle, Maria Lujan Ferreira. PLA Nano- and micro particles for drug delivery: an overview of method of preparations, Macromolecular Bioscience, 2007, 767-783.
- [23]. Vyas SP, Khar RK. Targeted and Controlled Drug Delivery Novel Carrier System, 1st Edition, New Delhi: Cbs Publishers and Distributers, 2002, 419-42.
- [24]. Putney SD, Burke PA. Improving Protein Therapeutics with Sustained Release Formulations, Nature Biotechnology. 1998;16:153-157.
- [25]. DandgelBh, Dehghan Mh. Formulation And Evaluation of Nasal Mucoadhesive Microparticles Of Diltiazem

- Hydrochloride. *Int J Chemtech Res.*, 2001; 1 (4): 1036-1042.
- [26]. Shoba Rani R, Hiremath. *Text Book of Industrial Pharmacy: Drug Delivery Systems, and Cosmetic and Herbal Technology.*, 117-127.
- [27]. James S. *Encyclopedia of Pharmaceutical Technology*, 2nd Edition: Marcel Dekker., 1990; 876-987.
- [28]. Das Sk, Das Ng. Preparation and In Vitro Dissolution Profile of Dual Polymer (Eudragit Rs100 And R1100) Microparticles Of Diltiazem Hydrochloride. *Microencapsul.*, 1998; 15(4): 445-52.
- [29]. Ertan G, Ozer O, Baloglu E and Guneri T, Sustained release microcapsules of nitrofurantion and amoxicillin preparation, invitro release rate kinetics and micrometric studies. *J. Microencap.*, 1997; 14: 379-388.
- [30]. Goto S, Moriya F, Kawata M and Kimura T, Preparation and biopharmaceutical evaluation of microcapsules of amoxicillin, *J. Microencap*, 1984; 1: 137-155.
- [31]. Alpar O H and Walter V, Prolongation of their vitro dissolution of a soluble drug (phenethicillin potassium) by microencapsulation with ethylcellulose. *J. Pharm. Pharmacol.*, 1981; 33: 419-422.
- [32]. Alpar O H., Sustained-release characteristics of tablets of ethylcellulose microcapsules containing potassium phenethicillin. *II. Pharmaco-Ed. Pr.*, 1980; 36: 366-373.
- [33]. Lu M F, Borodkin S, Woodward L and Vadnere M, Polymer carrier system for taste masking of macrolide antibiotics. *Pharm. Res.*, 1991; 8: 706-712.
- [34]. Friend D R, Polyacrylate resin microcapsules for taste masking of antibiotics. *J. Microencap.*, 1992; 9: 469-480.
- [35]. Tunçel T, Bergisadi N, Akin L, Otuk G and Kuscü I, In vitro and in vivo studies on microcapsules and tableted microcapsules of cephadrine. *Pharmacie*, 1996; 51: 168-171.
- [36]. Kristi A, Bogataj M, Mrhar A and Kozjeli F, Preparation and evaluation of ethylcellulose microcapsules with bacampicillin. *DrugDev. Ind. Pharm.*, 1991; 17: 1109-1130.
- [37]. Ueda M, Nakamura Y, Makita H and Kawashimo Y. One continuous process of agglomeration and microencapsulation forenoxacin. Preparation method and mechanism of microencapsulation. *J. Microencap.* 1993;10: 25-34.
- [38]. Jalil R and Nixon J, Microencapsulation with biodegradable materials. In: *Microencapsulation of Drugs*, 1992; 177-188.
- [39]. Madan P L, Madan DK and Price L C. The effect of pH on the fractionation of gelatine, *Can. J. Pharm. Sci.*, 1976; 11: 21-25.
- [40]. Paradissis GN and Parrot E L. Gelatin encapsulation of pharmaceuticals. *J. Clin. Pharmacol.* January- February, 54-59.
- [41]. Nixon, J. R. and Walker, S. E., 1971. The invitro evaluation of gelatine coacervate microcapsules. *J. Pharm. Pharmacol.*, 23(Suppl.): 1968; 147S-154S.
- [42]. Kondo T Microcapsules: their preparation and properties. In: *Surface and Colloid Science*, E. Matijevec (Ed.), Plenum Press, New York, 1978; 1-22
- [43]. Lu M F, Borodkin S, Woodward L and Vadnere M, Polymer carrier system for taste masking of macrolide antibiotics. *Pharm. Res.*, 1991; 8: 706-712.
- [44]. Tunçel T, Bergisadi N, Akin L, Otuk G and Kuscü I, In vitro and in vivo studies on microcapsules and tableted microcapsules of cephadrine. *Pharmacie*, 1996; 51: 168-171.
- [45]. Kristi A, Bogataj M, Mrhar A and Kozjeli F, Preparation and evaluation of ethylcellulose microcapsules with bacampicillin. *DrugDev. Ind. Pharm.*, 1991; 17: 1109-1130.
- [46]. Ueda M, Nakamura Y, Makita H and Kawashimo Y. One continuous process of agglomeration and microencapsulation forenoxacin. Preparation method and mechanism of microencapsulation. *J. Microencap.* 1993;10: 25-34.